NIOX issues new shares to CEO under deferred bonus plan, updates voting rights

Circassia Pharmaceuticals ( (GB:NIOX) ) has provided an update.

NIOX Group has issued 135,188 new ordinary shares to chief executive Jonathan Emms under its Deferred Share Bonus Plan, settling the deferred portion of his 2023 annual bonus in equity. The award, made from an existing block admission, lifts Emms’ holding to 3,399,076 shares, representing 0.813% of the company, and forms part of NIOX’s policy to align executive pay with long‑term shareholder interests.

Following this issuance, NIOX’s total share capital stands at 418,074,453 ordinary shares, each carrying one voting right. The updated share count will serve as the new reference point for investors assessing disclosure thresholds under U.K. transparency rules, slightly diluting existing holdings but clarifying the company’s current voting capital structure.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £66.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a U.K.-listed medical technology company focused on respiratory health diagnostics. The group develops and sells devices and related products used to measure fractional exhaled nitric oxide, helping clinicians to diagnose and manage asthma and other airway inflammatory conditions in global healthcare markets.

Average Trading Volume: 779,799

Technical Sentiment Signal: Sell

Current Market Cap: £242.4M

See more insights into NIOX stock on TipRanks’ Stock Analysis page.